Fibroblast Growth Factor-2 Human Recombinant (FGF-2) produced in E. Coli is a single, non-glycosylated, polypeptide chain containing 154 amino acids and having a molecular mass of 17.2kDa. The FGF-b is purified by proprietary chromatographic techniques.
Basic fibroblast growth factor is a member of the fibroblast growth factor (FGF) family. FGF family members possess broad mitogenic and cell survival activities, and are involved in a variety of biological processes, including embryonic development, cell growth, morphogenesis, tissue repair, tumor growth and invasion. This protein functions as a modifier of endothelial cell migration and proliferation, as well as an angiogenic factor. It acts as a mitogen for a variety of mesoderm- and neuroectoderm-derived cells in vitro, thus is thought to be involved in organogenesis. Three alternatively spliced variants encoding different isoforms have been described. The heparin-binding growth factors are angiogenic agents in vivo and are potent mitogens for a variety of cell types in vitro. There are differences in the tissue distribution and concentration of these 2 growth factors.
>98.0% as determined by: (a) Analysis by RP-HPLC. (b) Analysis by SDS-PAGE.
Sterile Filtered White lyophilized (freeze-dried) powder. The protein was lyophilized from a concentrated (1mg/ml) solution in PBS, pH 7.4.
The ED50, calculated by the dose-dependant proliferation of BAF3 cells expressing FGF receptors (measured by 3H-thymidine uptake) is <0.5 ng/ml, corresponding to a specific activity of 2,000,000 Units/mg.
It is recommended to reconstitute the lyophilized Fibroblast Growth Factor Basic in sterile 18MΩ-cm H2O not less than 100µg/ml, which can then be further diluted to other aqueous solutions.
This protein functions as a modifier of endothelial cell migration and proliferation, as well as an angiogenic factor.
Examples of Clinical Use:
Modifier of endothelial cell migration and proliferation
Basic Fibroblast Growth Factor (FGF-b) is also known as FGF2.
The protein encoded by this gene is a member of the fibroblast growth factor (FGF) family. FGF family members bind heparin and possess broad mitogenic and angiogenic activities. This protein has been implicated in diverse biological processes, such as limb and nervous system development, wound healing, and tumor growth. The mRNA for this gene contains multiple polyadenylation sites, and is alternatively translated from non-AUG (CUG) and AUG initiation codons, resulting in five different isoforms with distinct properties. The CUG-initiated isoforms are localized in the nucleus and are responsible for the intracrine effect, whereas, the AUG-initiated form is mostly cytosolic and is responsible for the paracrine and autocrine effects of this FGF.
Gene Ontology (GO) annotations related to this gene include cytokine activity and heparin binding. An important paralog of this gene is FGF1.
Three dimensional structures for FGF2 Gene
Diseases associated with FGF2 include Corneal Neovascularization and Chronic Ulcer Of Skin. Among its related pathways are Downstream signaling of activated FGFR2 and Apoptotic Pathways in Synovial Fibroblasts.
FGF2 acts as a ligand for FGFR1, FGFR2, FGFR3 and FGFR4. Also acts as an integrin ligand which is required for FGF2 signaling.
It binds to integrin ITGAV:ITGB3.
FGF2 plays an important role in the regulation of cell survival, cell division, cell differentiation and cell migration.
The gene functions as a potent mitogen in vitro.
FGF2 can induce angiogenesis. Also can mediates phosphorylation of ERK1/2 and thereby promotes retinal lens fiber differentiation
There are 61 pathways. Here are some of them. 14-3-3 Induced Intracellular Signaling Actin-Based Motility by Rho Family GTPases Activation of cAMP-Dependent PKA Activation of PKA through GPCR Activation of PKC through GPCR Akt Signaling Antioxidant Action of Vitamin-C Apoptotic Pathways in Synovial Fibroblasts Breast Cancer Regulation by Stathmin1 cAMP Pathway Cellular Apoptosis Pathway CREB Pathway DHA Signaling eIF2 Pathway eNOS Signaling Epithelial Adherens Junctions ERK Signaling ERK5 Signaling Estrogen Pathway Factors Promoting Cardiogenesis in Vertebrates FGF Pathway Glioma Invasiveness GPCR Pathway GSK3 Signaling Human Embryonic Stem Cell Pluripotency ILK Signaling Intracellular Calcium Signaling IP3 Pathway JAK-STAT Pathway JNK Pathway MAPK Family Pathway MAPK Signaling
About FGF2, there are 30 pipelines under study, 17 of which have been approved.
Sucralfate is a gastro-duodenal protective agent used in the treatment of gastric and duodenal ulcers and to prevent duodenal ulcer recurrence.
Thalidomide is a medication used to treat cancers, particularly newly diagnosed multiple myeloma, and erythema nodosum leprosum.
Parnaparin is a low molecular weight heparin (LMWH) used to prevent blood clots, specifically deep vein thrombosis.
Fluvoxamine is a selective serotonin-reuptake inhibitor used to treat obsessive-compulsive disorder.
Lenalidomide is a thalidomide derivative used to treat multiple myeloma and anemia in low to intermediate risk myelodysplastic syndrome.
Vincristine is a vinca alkaloid used to treat acute leukemia, malignant lymphoma, Hodgkin's disease, acute erythraemia, and acute panmyelosis.
Pentosan polysulfate is a sulfated pentosyl polysaccharide used to treat bladder pain and discomfort due to interstitial cystitis.
Sirolimus is an mTOR inhibitor immunosuppressant used to prevent organ transplant rejections, treat lymphangioleiomyomatosis, and treat adults with perivascular epithelioid cell tumors.
Atorvastatin is an HMG-CoA reductase inhibitor used to lower lipid levels and reduce the risk of cardiovascular disease including myocardial infarction and stroke.
Caffeine is a stimulant present in tea, coffee, cola beverages, analgesic drugs, and agents used to increase alertness. It is also used in to prevent and treat pulmonary complications of premature birth.
Indomethacin is a nonsteroidal anti-inflammatory (NSAID) used for symptomatic management of chronic musculoskeletal pain conditions and to induce closure of a hemodynamically significant patent ductus arteriosus in premature infants.
For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products
without prior written approval from Creative BioMart.
For more information on how our products could help advance your project, please contact us.